(2) Since ER-RTK crosstalk is also involved in aberrant signaling of other growth factors, FGFR1-induced ER-RTK crosstalk and palbociclib resistance may suggest CDKi resistance to cancers, with the deregulation of other growth factors/receptors, such as IGFIR. Here, IGF1R is linked to cancer.